Develops drugs for respiratory and infectious diseases.
Jun 2026Revenue $440M/yrExpenses $277M/yr
No trend
Figures by year
Is Innoviva profitable?
Yes. In the 12 months to Jun 2026, revenue was $440M and expenses $277M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $411M | $248M | $164M |
| Dec 2024 | $359M | $192M | $167M |
| Dec 2023 | $310M | $197M | $114M |
| Dec 2021 | $392M | $16.8M | $375M |
| Dec 2020 | $337M | $15.7M | $321M |
| Dec 2019 | $261M | $14.7M | $246M |
| Dec 2018 | $261M | $22.8M | $238M |
| Dec 2017 | $217M | $33.6M | $184M |
| Dec 2016 | $134M | $24.6M | $109M |
| Dec 2015 | $53.9M | $22.4M | $31.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.